Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-20

Clinical Trial Update: Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) [Phase 2]

View source ↗

Summary

Phase 2 RSV human challenge study MK-4482-017 in healthy participants has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Molnupiravir (molnupiravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Respiratory Syncytial Virus | Phase 2 | Status: COMPLETED | Results posted: 2024-05-20